As demonstrated by Cancer Profiling Arrays data in Figures 1 and 2, a high percentage of patients displayed a down-regulation of CHL1 expression in breast, kidney, rectum, colon, thyroid, stomach, skin, small intestine, bladder, vulva and pancreatic cancer. This evidence concerns the gene CHL1 and familial pancreatic carcinoma.